[Retracted] Using Haemocoagulase Agkistrodon in Patients Undergoing Transurethral Plasmakinetic Resection of the Prostate: A Pilot, Real-World, and Propensity Score-Matched Study

Table 1

Baseline characteristics of patients used haemocoagulase agkistrodon for injection or hemocoagulase for injection before and after propensity score matching.

Baseline	Before propensity score matching			After propensity score matching
	Haemocoagulase agkistrodon ()	Hemocoagulase ()		Haemocoagulase agkistrodon ()	Hemocoagulase ()
Age (years)	73.00 (66.00, 79.00)	71.00 (66.00, 76.00)	0.14	70.00 (65.00, 77.00)	69.00 (66.00, 76.00)	0.86
Body mass index (kg/m^2)	23.36 (20.62, 25.53)	23.05 (20.76, 24.57)	0.49			0.51
Prostate volume (mL)	51.65 (32.46, 81.68)	50.31 (38.73, 71.24)	0.96	54.05 (35.94, 70.01)	49.69 (37.35, 69.89)	0.67
Systolic pressure (mmHg)	132.00 (120.00, 142.00)	130.00 (120.00, 135.50)	0.21	130.00 (120.00, 140.00)	130.00 (120.00, 134.00)	0.54
Diastolic pressure (mmHg)			0.95			0.81
Fasting blood glucose (ng/mL)	5.11 (4.80, 5.60)	4.93 (4.40, 5.50)	0.05	5.06 (4.75, 5.57)	4.86 (4.40, 5.45)	0.09
Hypertension status ( [%])			0.38			0.21
Yes	12 (10.81%)	6 (7.14%)		8 (12.31%)	4 (6.15%)
No	99 (89.19%)	80 (92.86%)		57 (87.69%)	61 (93.85%)
History of smoking ( [%])			0.34			0.51
Yes	28 (25.23%)	27 (31.40%)		18 (27.69%)	15 (23.08%)
No	83 (74.77%)	59 (68.60%)		47 (72.31%)	50 (76.92%)
History of drinking ( [%])			0.57			0.55
Yes	29 (26.13%)	25 (29.76%)		19 (29.23%)	16 (24.62%)
No	82 (73.87%)	61 (70.24%)		46 (70.77%)	49 (75.38%)